DelveInsight’s “Post-Surgical Pain Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Post-Surgical Pain, historical and forecasted epidemiology as well as the Post-Surgical Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Post-Surgical Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Post-Surgical Pain Market Forecast

Some of the key facts of the Post-Surgical Pain Market Report:

• The Post-Surgical Pain market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In February 2025, Allay Therapeutics, a clinical-stage biotechnology company focused on ultra-sustained analgesic solutions for post-surgical pain management, has announced the dosing of the first patient in its Phase 2b registration trial evaluating ATX101 for post-surgical pain relief following total knee replacement (TKA) surgery. ATX101, a novel investigational analgesic, aims to deliver long-lasting pain relief, minimizing opioid dependence and enhancing patient recovery.

• In January 2024, Taiwan-based Xgene Pharmaceutical reported positive results from its Phase IIb study evaluating XG005, a non-opioid analgesic, for post-surgical acute pain relief. The placebo-controlled, dose-ranging trial (NCT06017999) assessed pain reduction using the summed pain index (SPI) over 48 hours following bunionectomy surgery. The study compared two doses of XG005 (1,250 mg and 750 mg) against a placebo to determine its efficacy.

• In November 2024, Averitas Pharma, the U.S. subsidiary of Grünenthal, has successfully completed patient enrollment for its Phase III AV001 clinical trial, evaluating QUTENZA (capsaicin) 8% topical system for the treatment of post-surgical neuropathic pain (PSNP).

• Several leading Post-Surgical Pain companies are advancing their key drug candidates through various stages of clinical development, including IV Tramadol by Avenue Therapeutics, Opiranserin (VVZ-149) Injections by Vivozon, OCS-01 by Oculis, among others.

• In 2023, the 7MM recorded approximately 67 million incident cases of Post-Surgical Pain. This number is projected to rise by 2032, driven by an increase in traffic accidents, trauma-related injuries, and the growing demand for pain management after surgeries.

• In 2023, the US accounted for the highest proportion of incident Post-Surgical Pain cases, contributing approximately 60.41% of the total cases in the 7MM. Meanwhile, EU4 and the UK represented around 21.14%, while Japan accounted for approximately 18.43% of the total cases.

• As per DelveInsight, in 2023, the estimated severity-specific incident cases of Post-Surgical Pain in France were approximately 1.2 million mild cases, 1.5 million moderate cases, and 0.8 million severe cases. These numbers are projected to rise by 2032 due to an increasing incidence of Post-Surgical Pain.

• In 2023, the estimated severity-specific incident cases of Post-Surgical Pain in Germany were approximately 1.4 million mild cases, 1.7 million moderate cases, and 1 million severe cases. These figures are projected to rise throughout the forecast period (2023–2032).

• In the UK, around 4,050,000 new cases of Post-Surgical Pain were reported in 2023.

• Key Post-Surgical Pain Companies: Ocular Therapeutix, Heron Therapeutics, Avenue Therapeutics, Taiwan Liposome Company (TLC), Teikoku Pharma USA, Concentric Analgesics, Salvat Laboratories, Vertex Pharmaceuticals, Oculis, Baudax Bio, Jiangsu HengRui Medicine, Darnitsa Pharma, Adynxx, Inc., Pacira Pharma, Apsen Farmaceutica S.A., Durect, Pfizer, Vivozon, Inc., Grünenthal GmbH, Mallinckrodt, Astellas Pharma Inc, Ferndale Laboratories, Inc., and others

• Key Post-Surgical Pain Therapies: DEXTENZA (dexamethasone), ZYNRELEF (bupivacaine and meloxicam), IV Tramadol, TLC590, TPU-006, CA-008, SVT-15473, VX-548, OCS-01, N1539, SHR0410, Ketorolac tromethamine, AYX1, EXPAREL, Toragesic®, SABER-Bupivacaine, lyrica, VVZ-149, Tapentadol (OS), Percocet, YM177, LMX4, and others

• The Post-Surgical Pain market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Post-Surgical Pain pipeline products will significantly revolutionize the Post-Surgical Pain market dynamics.

Post-Surgical Pain Overview

Post-Surgical Pain is discomfort or pain experienced after a surgical procedure due to tissue trauma, nerve damage, or inflammation. It can be acute (short-term) or chronic (lasting beyond the normal healing period, usually over three months).

Pain levels vary based on the type of surgery, individual pain tolerance, and pre-existing conditions. Management includes medications (opioids, NSAIDs, local anesthetics), physical therapy, and nerve blocks to enhance recovery and prevent complications. Proper pain control is crucial to improving patient outcomes and reducing the risk of chronic pain development.

Get a Free sample for the Post-Surgical Pain Market Report:

https://www.delveinsight.com/report-store/post-surgical-pain-market

Post-Surgical Pain Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Post-Surgical Pain Epidemiology Segmentation:

The Post-Surgical Pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Number of Incident Cases of Post-Surgical Pain in the 7MM

• Total Number of Surgical Procedures(inpatient and outpatient) in the 7MM

• Severity-specific Incident Cases of Post-Surgical Pain in the 7MM

Download the report to understand which factors are driving Post-Surgical Pain epidemiology trends @ Post-Surgical Pain Epidemiology Forecast

Post-Surgical Pain Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Post-Surgical Pain market or expected to get launched during the study period. The analysis covers Post-Surgical Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Post-Surgical Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Post-Surgical Pain Therapies and Key Companies

• DEXTENZA (dexamethasone): Ocular Therapeutix

• ZYNRELEF (bupivacaine and meloxicam): Heron Therapeutics

• IV Tramadol: Avenue Therapeutics

• TLC590: Taiwan Liposome Company (TLC)

• TPU-006: Teikoku Pharma USA

• CA-008: Concentric Analgesics

• SVT-15473: Salvat Laboratories

• VX-548: Vertex Pharmaceuticals

• OCS-01: Oculis

• N1539: Baudax Bio

• SHR0410: Jiangsu HengRui Medicine

• Ketorolac tromethamine: Darnitsa Pharma

• AYX1: Adynxx, Inc.

• EXPAREL: Pacira Pharma

• Toragesic®: Apsen Farmaceutica S.A.

• SABER-Bupivacaine: Durect

• lyrica: Pfizer

• VVZ-149: Vivozon, Inc.

• Tapentadol (OS): Grünenthal GmbH

• Percocet: Mallinckrodt

• YM177: Astellas Pharma Inc

• LMX4: Ferndale Laboratories, Inc.

Discover more about therapies set to grab major Post-Surgical Pain market share @ Post-Surgical Pain Treatment Market

Post-Surgical Pain Market Strengths

• Drugs with a novel mechanism of action would provide new treatment options to the patients. For instance, SVT-15473 is a “superpotent” corticosteroid that has never been used before as eye drops.

• Upcoming therapies are majorly non-opioids which are as effective, and this would reduce opioid dependence and other safety concerns associated with the current opioid medications.

Post-Surgical Pain Market Opportunities

• Increased public awareness creates a lucrative opportunity for the innovation of therapeutics to drive this market.

• Multimodal treatments can be prescribed to reduce the dependency on single-modal treatment. Launching such products will increase the potential ability to treat Post-Surgical Pain.

Scope of the Post-Surgical Pain Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Post-Surgical Pain Companies: Ocular Therapeutix, Heron Therapeutics, Avenue Therapeutics, Taiwan Liposome Company (TLC), Teikoku Pharma USA, Concentric Analgesics, Salvat Laboratories, Vertex Pharmaceuticals, Oculis, Baudax Bio, Jiangsu HengRui Medicine, Darnitsa Pharma, Adynxx, Inc., Pacira Pharma, Apsen Farmaceutica S.A., Durect, Pfizer, Vivozon, Inc., Grünenthal GmbH, Mallinckrodt, Astellas Pharma Inc, Ferndale Laboratories, Inc., and others

• Key Post-Surgical Pain Therapies: DEXTENZA (dexamethasone), ZYNRELEF (bupivacaine and meloxicam), IV Tramadol, TLC590, TPU-006, CA-008, SVT-15473, VX-548, OCS-01, N1539, SHR0410, Ketorolac tromethamine, AYX1, EXPAREL, Toragesic®, SABER-Bupivacaine, lyrica, VVZ-149, Tapentadol (OS), Percocet, YM177, LMX4, and others

• Post-Surgical Pain Therapeutic Assessment: Post-Surgical Pain current marketed and Post-Surgical Pain emerging therapies

• Post-Surgical Pain Market Dynamics: Post-Surgical Pain market drivers and Post-Surgical Pain market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Post-Surgical Pain Unmet Needs, KOL’s views, Analyst’s views, Post-Surgical Pain Market Access and Reimbursement

To know more about Post-Surgical Pain companies working in the treatment market, visit @ Post-Surgical Pain Clinical Trials and Therapeutic Assessment

Table of Contents

1. Post-Surgical Pain Market Report Introduction

2. Executive Summary for Post-Surgical Pain

3. SWOT analysis of Post-Surgical Pain

4. Post-Surgical Pain Patient Share (%) Overview at a Glance

5. Post-Surgical Pain Market Overview at a Glance

6. Post-Surgical Pain Disease Background and Overview

7. Post-Surgical Pain Epidemiology and Patient Population

8. Country-Specific Patient Population of Post-Surgical Pain

9. Post-Surgical Pain Current Treatment and Medical Practices

10. Post-Surgical Pain Unmet Needs

11. Post-Surgical Pain Emerging Therapies

12. Post-Surgical Pain Market Outlook

13. Country-Wise Post-Surgical Pain Market Analysis (2019–2032)

14. Post-Surgical Pain Market Access and Reimbursement of Therapies

15. Post-Surgical Pain Market Drivers

16. Post-Surgical Pain Market Barriers

17. Post-Surgical Pain Appendix

18. Post-Surgical Pain Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/